ClinicalTrials.gg
CompletedNCT00094055Updated Jun 26, 2012Results posted

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

A Phase 2 interventional study of AG013736 in Thyroid Neoplasms, sponsored by Pfizer. Completed at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-26.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 283 studies in Thyroid Neoplasms with a site in United States — 54 open to participants now, 90 under way, 3 of them phase 3. Thyroid Neoplasms · United States.

Enrollment
74th of 231
60 · median 35
Started
2004
with 12 others
Phase 2
99 of 283
12 open now
Registered
15th of 283
by date
Lead sponsor
5 of 283
Pfizer

Among the 283 studies in Thyroid Neoplasms with a site in United States, this one is the 74th largest by enrollment of the 231 interventional ones that give a count, is one of 13 that started in 2004, is one of 99 in phase 2, and was the 15th registered.

Thyroid Neoplasms

785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.

Browse Thyroid Neoplasms studies →

Open to participants now

54 of the 283 studies in Thyroid Neoplasms with a site in United States are open now. Recruiting first, the newest first:

49 more — sign in →

All 54 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Thyroid Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 study being conducted at multiple centers in the United States. Patients having thyroid cancer that has spread to other parts of the body (i.e., metastatic) are eligible to participate. Patients must have disease that was not controlled by previous treatment with radioactive iodine (131I) or not be good candidates for such treatment. The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic thyroid cancer as shown by the number of patients in the study who experience significant and durable tumor shrinkage.

03

Conditions studied

  • Thyroid Neoplasms

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • documented thyroid cancer with .
  • Failure of radioactive iodine (131I) to control the disease or radioactive iodine (131I) is not an appropriate therapy (e.g. due to lack of iodine uptake by the tumor)

Exclusion criteria

Exclusion Criteria:

  • Central lung lesions involving major blood vessels (arteries or veins).(Central lesions that maintain the structural integrity of vessels have the potential to bleed if the tumor lesion undergoes necrosis. MRI or CT angiography should be used in any case where there is any question as to whether blood vessels are involved.)
  • Patients with a history of hemoptysis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Axitinib [AG-013736]

    Drug: AG013736

Interventions

  • AG013736, tablets 5 mg BID daily until tumor progression or toxicity

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (OR)

    Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

    Time frame: Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 206 weeks

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

    Time frame: Baseline to disease progression or death due to any cause, assessed every 8 weeks up to 206 weeks

  2. Duration of Response (DR)

    Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

    Time frame: Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 206 weeks

  3. Overall Survival (OS)

    Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

    Time frame: Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant

Other outcomes

  1. Population Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations

    Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.

    Time frame: Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 206 weeks

  2. Plasma Concentrations of Soluble Proteins

    Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

    Time frame: Day 1 (pre-dose) and then every 8 weeks up to 206 weeks

07

Results

Posted Mar 30, 2012
Limitations and caveats
Population pharmacokinetics and plasma concentrations of soluble proteins were not presented, as the data was not available for the single study and data for all the axitinib (AG-013736) Phase 2 studies would be pooled together in a separate report.

Participant flow

Participant flow — Overall Study
MilestoneAxitinib
Started60
Completed0
Not completed60
Withdrew: Adverse event11
Withdrew: Death4
Withdrew: Lack of efficacy17
Withdrew: Lost to follow-up2
Withdrew: Progressive disease2
Withdrew: Clinical progression1
Withdrew: Roll-over to another study14
Withdrew: Withdrawal by subject9

Outcome measures

PrimaryPercentage of Participants With Objective Response (OR)

Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as the disappearance of all lesions (target and/or non target). PR are those with at least 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.

Time frame:
Baseline until the date of first documented progression or discontinuation from the study due to any cause, assessed every 8 weeks up to 206 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants With Objective Response (OR)
Percentage of participantsAxitinib
Percentage of Participants With Objective Response (OR)38.3 (26.1 to 51.8)
SecondaryProgression-Free Survival (PFS)

Time in days from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1). Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \[PD\]), or from adverse event (AE) data (where the outcome was "Death").

Time frame:
Baseline to disease progression or death due to any cause, assessed every 8 weeks up to 206 weeks
Reported as:
Median · Days
Progression-Free Survival (PFS)
DaysAxitinib
Progression-Free Survival (PFS)459 (302 to 610)
SecondaryDuration of Response (DR)

Time in days from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1. DR was calculated for the subgroup of participants with a confirmed objective tumor response.

Time frame:
Baseline to disease progression or discontinuation from study due to any cause, assessed every 8 weeks up to 206 weeks
Reported as:
Median · Days
Duration of Response (DR)
DaysAxitinib
Duration of Response (DR)625 (382 to 1391)
SecondaryOverall Survival (OS)

Time in days from the start of study treatment to date of death due to any cause. OS was calculated as the death date minus the date of first dose of study medication plus 1. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death). For participants who were alive, overall survival was censored at the last contact.

Time frame:
Baseline to death due to any cause or at least 1 year after the initial dose for the last treated participant
Reported as:
Median · Days
Overall Survival (OS)
DaysAxitinib
Overall Survival (OS)1068 (568 to NA)
Other pre-specifiedPopulation Pharmacokinetics for Axitinib (AG-013736) Plasma Concentrations

Population pharmacokinetic analysis involved mixed effects modeling using nonlinear mixed effects modeling (NONMEM) software. The intent of this analysis was to establish a basic population pharmacokinetic model for axitinib (AG-013736) and to determine inter-individual and residual variability in population (oral) clearance, and volume of distribution of drug. Relationship of demographic variables (gender, age, body weight, height and ethnicity), concomitant medications and measures of altered hepatic and renal function were examined by fitting measured axitinib (AG-013736) concentrations.

Time frame:
Day 1 (pre-dose), Day 29, Day 57 and then every 8 weeks up to 206 weeks
Reported as:
Mean · nanogram/milliliter (ng/mL)

No measurements were reported for this outcome.

Other pre-specifiedPlasma Concentrations of Soluble Proteins

Plasma concentrations of soluble proteins (vascular endothelial growth factor \[VEGF\], placental growth factor \[PlGF\] and soluble vascular endothelial growth factor receptor-2 \[sVEGFR2\]) may be associated with tumor angiogenesis or tumor physiology and may correlate with efficacy or biological activity. It is presented as ratio to baseline, which is obtained by dividing the plasma soluble protein concentration at each time point by its concentration at baseline.

Time frame:
Day 1 (pre-dose) and then every 8 weeks up to 206 weeks
Reported as:
Mean · Ratio

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Axitinib—32/60 (53.3%)60/60 (100%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventAxitinib
Dyspnoea NOSRespiratory, thoracic and mediastinal disorders6/60
DehydrationMetabolism and nutrition disorders4/60
Chest painGeneral disorders3/60
Disease progression NOSGeneral disorders3/60
DysphagiaGastrointestinal disorders2/60
Pneumonia NOSInfections and infestations2/60
AnorexiaMetabolism and nutrition disorders2/60
Headache NOSNervous system disorders2/60
Airway obstruction NOSRespiratory, thoracic and mediastinal disorders2/60
HypoxiaRespiratory, thoracic and mediastinal disorders2/60
Most frequent other events
Showing 10 of 115
Most frequent other events
EventAxitinib
FatigueGeneral disorders42/60
DiarrhoeaGastrointestinal disorders40/60
NauseaGastrointestinal disorders30/60
Decreased appetiteMetabolism and nutrition disorders28/60
HypertensionVascular disorders28/60
HeadacheNervous system disorders27/60
DyspepsiaGastrointestinal disorders24/60
Weight decreasedInvestigations24/60
CoughRespiratory, thoracic and mediastinal disorders23/60
DyspnoeaRespiratory, thoracic and mediastinal disorders21/60

Baseline characteristics

Age Continuous
Age Continuous(years)Axitinib
Mean59.3 ± 13.7
Sex: Female, Male
Sex: Female, Male(Participants)Axitinib
Female25
Male35
08

Study locations

9 sites
  • Pfizer Investigational Site
    Santa Monica, California 90404, United States
  • Pfizer Investigational Site
    Aurora, Colorado 80010, United States
  • Pfizer Investigational Site
    Denver, Colorado 80220, United States
  • Pfizer Investigational Site
    Chicago, Illinois 60637, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 21231-1000, United States
  • Pfizer Investigational Site
    Baltimore, Maryland 51231, United States
  • Pfizer Investigational Site
    Ann Arbor, Michigan 48109, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • Pfizer Investigational Site
    Houston, Texas 77030-4009, United States
09

References and documents

Publications

  • Cohen EE, Tortorici M, Kim S, Ingrosso A, Pithavala YK, Bycott P. A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014 Dec;74(6):1261-70. doi: 10.1007/s00280-014-2604-8. Epub 2014 Oct 15. PubMed 25315258 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Jan 2009 and a completion of Jan 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2012, 3 years 2 months after primary completion. A results delay was requested in Mar 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2004
First posted
Oct 11, 2004
Start
Sep 2004
Primary completionActual
Jan 2009
CompletionActual
Jan 2009
Results delay requested
Mar 20, 2009
Results first posted
Mar 30, 2012
Last update
Jun 26, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00094055
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 11, 2004
Start date
Sep 2004
Primary completion
Jan 2009
Completion
Jan 2009
Results posted
Mar 30, 2012
Last update
Jun 26, 2012

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axitinib

Start the discussion